Unlocking the therapeutic force of omega-3 fatty acid metabolites with our 1st-in-class therapeutics, targeting both #Inflammation and #MitochdrialDysfunction
Location: Germany, Berlin
Employees: 11-50
Total raised: $37.45M
Founded date: 2013
Investors 2
| Date | Name | Website |
| 19.05.2025 | Forbion | forbion.co... |
| 17.07.2021 | High-Tech ... | htgf.de |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 21.06.2023 | Grant | $2.73M | - |
| 02.11.2018 | Series C | $19.36M | Forbion |
| 01.03.2017 | Series B | $8.74M | - |
| 15.04.2015 | Series A | $6.62M | - |
Mentions in press and media 13
| Date | Title | Description |
| 21.06.2023 | OMEICOS Therapeutics Receives 2.5 million Euros in Grant Funding Supporting OMT-28’s Development in Mitochondrial Diseases Through a Phase 2a Clinical Study | BERLIN, GERMANY, June 21, 2023 – OMEICOS, a biopharmaceutical company developing first-in-class small molecule therapeutics based on the profound understanding of omega-3 fatty acid metabolism and physiology, announced today that the Compan... |
| 09.10.2021 | Top 10 Healthcare Startups in Germany | The global healthcare market is expected to reach USD 11,908.9 billion by 2022, growing at a CAGR of 8.9%. Germany stands as the 3rd largest market for healthcare and medical products and is No. 1 in Europe, and the country’s healthcare ind... |
| 05.11.2018 | Term Sheet — Monday, November 5 | MASA WATCH 2018 Good morning, Term Sheet readers. Paid Content What you need to know about growing cyberattacks From ExtraHop On Friday, we discussed Softbank’s awkward position after it publicly touted that Saudi Arabia’s Public Investment... |
| 02.11.2018 | Omeicos scores $19.5M in Series C to take its omega-3 drug to the next round | Berlin-based Omeicos Therapeutics has closed €17 million in Series C financing, money the cardio-and-eye focused biotech says it’ll use to take its lead drug OMT-28 into a phase II to study in patients with persistent afib. R... |
| 02.11.2018 | Berlin-based OMEICOS Therapeutics has raised €17 million to develop treatments for heart arrhythmia | Berlin-based OMEICOS Therapeutics, a biopharmaceutical company that specializes in preventing and treating cardiovascular and ophthalmic diseases, has just raised €17 million in Series C financing. Founded in 2013, OMEICOS’ mission is to de... |
| 02.11.2018 | Omeicos raises €17M to run phase 2 atrial fibrillation trial | Omeicos Therapeutics has raised €17 million ($19 million) to develop an atrial fibrillation candidate. The Forbion-led series C round sets Omeicos up to run a phase 2 trial of its small molecule analogue of a natural omega-3 fatty acid meta... |
| 02.11.2018 | Omeicos raises €17M to run phase 2 atrial fibrillation trial W h i t e p a p e r Weighing the Costs: | Omeicos Therapeutics has raised €17 million ($19 million) to develop an atrial fibrillation candidate. The Forbion-led series C round sets Omeicos up to run a phase 2 trial of its small molecule analogue of a natural omega-3 fatty acid meta... |
| 02.11.2018 | Omeicos Therapeutics Raises €17M in Series C Financing | Omeicos Therapeutics, a Berlin, Germany-based biopharmaceutical company, raised €17m in Series C financing. The round was led by Forbion, contributing €12.5m from its recently launched Forbion IV Fund, with participation from existing inves... |
| 02.11.2018 | Top tech startup news stories you need to know this Friday, November 2 | Good morning! Here are some of the top tech startup news stories for today, Friday, November 2. Expedia acquires 2 venture-backed hospitality startups, Pillow and ApartmentJet. Expedia has acquired venture-backed hospitality startups Pillo... |
| 05.10.2017 | Omeicos Raises Series B Financing Round Extension | Omeicos Therapeutics, a Berlin, Germany-based biopharmaceutical company developing small molecule therapeutics for the prevention and treatment of cardiovascular diseases, secured an extension of a Series B financing round. The financial de... |
Show more